bioMerieux
Investments
18Portfolio Exits
7Partners & Customers
10About bioMerieux
bioMerieux (Paris:BIM), operates within the field of in vitro diagnostics, provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's products are used for diagnosing infectious diseases and providing high medical value results for cancer screening, monitoring and cardiovascular emergencies.
bioMerieux Headquarter Location
100, Allee Louis Pasteur
Marcy L'Etoile, 69280,
France
0 820 22 3000
Expert Collections containing bioMerieux
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find bioMerieux in 3 Expert Collections, including Pharma Startups.
Pharma Startups
5,090 items
Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.
Infectious Disease
2,225 items
Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.
Health Monitoring & Diagnostics
701 items
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
bioMerieux Web Traffic
bioMerieux Rank
Latest bioMerieux News
Oct 22, 2021
Amid the COVID-19 crisis, the global market for Clinical Diagnostics Automation estimated at US$4.1 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 8.2% over the period 2020-2027. The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 12.4% CAGR The Clinical Diagnostics Automation market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 12.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR. Select Competitors (Total 52 Featured): Abaxis Inc. Recent Market Activity End-User and Technology-Led Aspects Drive Demand for Automation Key Factors Encouraging Laboratories to Adopt Automation - In a Nutshell Desire to Expand Bottom Lines Automation Liberates Patients from Risk of Pre-analytical Diagnostic Errors Lack of Skilled Workforce Rising Healthcare Costs and Pressing Need for Quality Testing Clinical Diagnostics Automation Insulate Effects of Tightening Labor Market Demographic Shifts & Societal Changes Drive Demand for Greater Clinical Care Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Microplate instrumentation - An Integral Component of Lab Automation Market Modular Automation Surges Ahead of TLA in Adoption Automation Plays an Important Role in Patient Treatment Management Automation in Immunohistochemistry offers High Throughput Capabilities Demand for Automated Hematology Analyzers on Rise Technological Advancements Drive Growth in the Global Automated Biochemistry Analyzers Market Automated Multiplexing Technology and its Role in Clinical Diagnostics Automation Microbiology Laboratories Vie for Automation High-End Microplate Washers Offer Enhanced Capabilities Laboratory Information System - A Key Aspect of Clinical Diagnostics Automation Operational Concerns Associated with LIS Bar Code Technology Continues to Gain Adoption in Clinical Settings 4. GLOBAL MARKET PERSPECTIVE
bioMerieux Investments
18 Investments
bioMerieux has made 18 investments. Their latest investment was in Accellix as part of their Series D on June 6, 2020.
bioMerieux Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/11/2020 | Series D | Accellix | $9.5M | Yes | 2 | |
12/4/2017 | Series B | Qvella | $20M | Yes | 7 | |
1/19/2017 | Series A - V | Banyan Biomarkers | $7M | Yes | 1 | |
1/10/2014 | Series C | |||||
11/16/2012 | Series C |
Date | 6/11/2020 | 12/4/2017 | 1/19/2017 | 1/10/2014 | 11/16/2012 |
|---|---|---|---|---|---|
Round | Series D | Series B | Series A - V | Series C | Series C |
Company | Accellix | Qvella | Banyan Biomarkers | ||
Amount | $9.5M | $20M | $7M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 7 | 1 |
bioMerieux Portfolio Exits
7 Portfolio Exits
bioMerieux has 7 portfolio exits. Their latest portfolio exit was BioTheranostics on January 05, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
1/5/2021 | Acquired | 17 | |||
Date | 1/5/2021 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 17 |
bioMerieux Acquisitions
10 Acquisitions
bioMerieux acquired 10 companies. Their latest acquisition was Hybiome Biomedical on June 06, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/6/2019 | Corporate Majority | Corporate Majority - II | 1 | |||
2/7/2019 | Unattributed | $17.51M | Acquired | 4 | ||
11/9/2018 | Corporate Majority | Corporate Majority | 2 | |||
4/4/2018 | Series F | |||||
1/21/2016 | Loan |
Date | 6/6/2019 | 2/7/2019 | 11/9/2018 | 4/4/2018 | 1/21/2016 |
|---|---|---|---|---|---|
Investment Stage | Corporate Majority | Unattributed | Corporate Majority | Series F | Loan |
Companies | |||||
Valuation | |||||
Total Funding | $17.51M | ||||
Note | Corporate Majority - II | Acquired | Corporate Majority | ||
Sources | 1 | 4 | 2 |
bioMerieux Partners & Customers
10 Partners and customers
bioMerieux has 10 strategic partners and customers. bioMerieux recently partnered with Specific Diagnostics on June 6, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
6/29/2021 | Licensor | Specific Diagnostics | United States | bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL ® Rapid AST system in Europe | 3 |
10/8/2020 | Partner | Africa Medical Supplies Platform | Rwanda | We have been working relentlessly to expand choice & quality of supplies and that is why this partnership with bioMérieux is very important to us , '' said African Union Special Envoy , Strive Masiyiwa . | 1 |
3/26/2020 | Partner | Novartis, Pfizer, Sanofi, Boehringer Ingelheim, Bd Biosciences, Eisai, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., and Merck KGaA | Switzerland, United States, France, Germany, Japan, and United Kingdom | Basel , March 26 , 2020 -- Today , Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development , manufacture and delivery of vaccines , diagnostics , and treatments for COVID-19 in response to the pandemic . | 5 |
1/4/2020 | Vendor | ||||
11/18/2019 | Partner |
Date | 6/29/2021 | 10/8/2020 | 3/26/2020 | 1/4/2020 | 11/18/2019 |
|---|---|---|---|---|---|
Type | Licensor | Partner | Partner | Vendor | Partner |
Business Partner | Specific Diagnostics | Africa Medical Supplies Platform | Novartis, Pfizer, Sanofi, Boehringer Ingelheim, Bd Biosciences, Eisai, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., and Merck KGaA | ||
Country | United States | Rwanda | Switzerland, United States, France, Germany, Japan, and United Kingdom | ||
News Snippet | bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL ® Rapid AST system in Europe | We have been working relentlessly to expand choice & quality of supplies and that is why this partnership with bioMérieux is very important to us , '' said African Union Special Envoy , Strive Masiyiwa . | Basel , March 26 , 2020 -- Today , Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development , manufacture and delivery of vaccines , diagnostics , and treatments for COVID-19 in response to the pandemic . | ||
Sources | 3 | 1 | 5 |
bioMerieux Team
11 Team Members
bioMerieux has 11 team members, including former Chief Executive Officer, Christopher R Hibberd.
Name | Work History | Title | Status |
|---|---|---|---|
Christopher R Hibberd | Chief Executive Officer | Former | |
Albert A Luderer | President, Chief Operating Officer | Former | |
Laurent Amat | Mapei, Enterprise, Marine Aluminium, MHWirth, Fjords Processing, Kvaerner, Aker Solutions, General Electric, and Hyatt Hotels | Chief Financial Officer | Former |
Stéphane Guerido | Guerbet, BNP Paribas, and Kodak | Chief Financial Officer | Former |
Laurent Thiery | Sanofi Pasteur | Chief Financial Officer | Former |
Name | Christopher R Hibberd | Albert A Luderer | Laurent Amat | Stéphane Guerido | Laurent Thiery |
|---|---|---|---|---|---|
Work History | Mapei, Enterprise, Marine Aluminium, MHWirth, Fjords Processing, Kvaerner, Aker Solutions, General Electric, and Hyatt Hotels | Guerbet, BNP Paribas, and Kodak | Sanofi Pasteur | ||
Title | Chief Executive Officer | President, Chief Operating Officer | Chief Financial Officer | Chief Financial Officer | Chief Financial Officer |
Status | Former | Former | Former | Former | Former |